📊 ADIL Key Takeaways
Is Adial Pharmaceuticals, Inc.. (ADIL) a Good Investment?
Adial Pharmaceuticals is a pre-revenue or non-operating pharmaceutical company with severe fundamental weaknesses, including $8.0M net losses, negative operating cash flow of $6.5M, and zero revenue generation. The company is essentially burning through its limited cash reserves ($5.9M) while consuming approximately $6.6M in annual free cash flow, indicating a runway of less than one year without additional financing or revenue inflection.
ADIAL appears to be a pre-revenue biotech with no current operating income base, persistent losses, and negative free cash flow. While the balance sheet is relatively clean with high cash, low liabilities, and no long-term debt, the current cash balance does not comfortably cover the recent annual cash burn, which raises funding and dilution risk. Losses have improved year over year, but the improvement is not yet supported by commercial revenue or proven operating leverage.
Why Buy Adial Pharmaceuticals, Inc.. Stock? ADIL Key Strengths
- Strong liquidity position with current ratio of 4.42x and $5.9M in cash
- Zero long-term debt provides clean balance sheet structure
- Low liability burden at $1.4M relative to $6.7M in total assets
- Strong liquidity with $5.88M in cash and 4.42x current and quick ratios
- No meaningful debt burden, reducing solvency pressure
- Net loss and diluted EPS improved materially year over year
ADIL Stock Risks: Adial Pharmaceuticals, Inc.. Investment Risks
- No revenue generation indicates lack of commercialized products or active business operations
- Operating losses of $7.8M with negative operating cash flow of $6.5M demonstrates unsustainable cash burn
- Cash runway of approximately 11 months at current burn rate creates critical liquidity risk without additional financing or revenue generation
- Severely negative ROE (-151.2%) and ROA (-119.5%) indicate capital destruction
- Interest coverage of -76.0x reflects inability to cover any debt service from operations
- Zero insider Form 4 filings in last 90 days suggests lack of insider confidence or activity
- No revenue base, making the business entirely dependent on external financing and pipeline progress
- Negative operating cash flow and free cash flow imply limited cash runway
- Very weak profitability metrics including deeply negative ROE and ROA signal poor capital efficiency
Key Metrics to Watch
- Revenue generation and product commercialization progress
- Monthly cash burn rate and runway to profitability or additional financing
- Operating cash flow trajectory and path to positive operations
- Pipeline advancement and clinical trial progress for pharmaceutical candidates
- Quarterly operating cash burn relative to cash on hand
- Progress toward revenue generation or late-stage clinical/regulatory milestones
Adial Pharmaceuticals, Inc.. (ADIL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.42x current ratio provides a solid financial cushion.
ADIL Profit Margin, ROE & Profitability Analysis
ADIL vs Healthcare Sector: How Adial Pharmaceuticals, Inc.. Compares
How Adial Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adial Pharmaceuticals, Inc.. Stock Overvalued? ADIL Valuation Analysis 2026
Based on fundamental analysis, Adial Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adial Pharmaceuticals, Inc.. Balance Sheet: ADIL Debt, Cash & Liquidity
ADIL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adial Pharmaceuticals, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-68.01 indicates the company is currently unprofitable.
ADIL Revenue Growth, EPS Growth & YoY Performance
Adial Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
ADIL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adial Pharmaceuticals, Inc.. (CIK: 0001513525)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADIL
What is the AI rating for ADIL?
Adial Pharmaceuticals, Inc.. (ADIL) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADIL's key strengths?
Claude: Strong liquidity position with current ratio of 4.42x and $5.9M in cash. Zero long-term debt provides clean balance sheet structure. ChatGPT: Strong liquidity with $5.88M in cash and 4.42x current and quick ratios. No meaningful debt burden, reducing solvency pressure.
What are the risks of investing in ADIL?
Claude: No revenue generation indicates lack of commercialized products or active business operations. Operating losses of $7.8M with negative operating cash flow of $6.5M demonstrates unsustainable cash burn. ChatGPT: No revenue base, making the business entirely dependent on external financing and pipeline progress. Negative operating cash flow and free cash flow imply limited cash runway.
What is ADIL's revenue and growth?
Adial Pharmaceuticals, Inc.. reported revenue of N/A.
Does ADIL pay dividends?
Adial Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find ADIL SEC filings?
Official SEC filings for Adial Pharmaceuticals, Inc.. (CIK: 0001513525) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADIL's EPS?
Adial Pharmaceuticals, Inc.. has a diluted EPS of $-11.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADIL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Adial Pharmaceuticals, Inc.. has a SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ADIL stock overvalued or undervalued?
Valuation metrics for ADIL: ROE of -151.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ADIL stock in 2026?
Our dual AI analysis gives Adial Pharmaceuticals, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADIL's free cash flow?
Adial Pharmaceuticals, Inc..'s operating cash flow is $-6.5M, with capital expenditures of $64.6K.
How does ADIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -151.2% (avg: 15%), current ratio 4.42 (avg: 2).